BD Announces Second Fiscal Quarter Results; Reaffirms Fiscal 2021 Guidance - Second fiscal quarter revenues of $4.9 billion grew 15.4% on a reported basis. On a currency-neutral basis, revenues increased 12.2%. - BD's COVID-19 testing sales were $480 million, including BD Veritor™ Plus System revenues of $290 million. - BD's core growth led by strong growth in Medication Delivery Solutions (up 10.4%), Pharmaceutical Systems (up 15.4%), and Biosciences (up 16.3%) on a reported basis. - Second fiscal quarter GAAP diluted earnings per share (EPS) increased 77.4% year-over-year to $0.94. - Adjusted EPS increased 25.1% year-over-year to $3.19. - BD is reaffirming its fiscal 2021 revenue growth and adjusted EPS guidance. News provided by Share this article